Patent: 7,858,390
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 7,858,390
Title: | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
Abstract: | Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a colorectal cancer (CRC) patient is likely to benefit from a drug targeting an epidermal growth factor receptor pathway, such as monoclonal antibody EGFR inhibitors. |
Inventor(s): | Roder; Heinrich (Steamboat Springs, CO), Tsypin; Maxim (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO) |
Assignee: | Biodesix, Inc. (Steamboat Springs, CO) |
Application Number: | 12/321,394 |
Patent Claims: | see list of patent claims |
Details for Patent 7,858,390
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2026-03-31 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2026-03-31 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2026-03-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |